SAT0109 Relationship Between Early Disease Activity Status and Structural and Functional Changes In Mtx-NaÏVe Patients with Early RA Treated with Abatacept Plus Mtx Versus Mtx Alone in the Agree Trial
Authors: J. S. Smolen, Y. Yazici, J. Wollenhaupt, P. Durez, J. Gomez-Reino, W. Grassi, M. Le Bars, C. Gaillez, C. Poncet, R. Westhovens
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In patients (pts) with early RA receiving MTX, remission improves long-term functional and structural outcomes. However, dissociation between clinical and structural outcomes has been reported with biologic treatment of early RA in pts with poor prognostic factors. <h3>Objectives</h3> To explore changes in structural and functional outcomes at Month(M)12 according to disease activity at M3 in the AGREE trial. <h3>Methods</h3> In AGREE, pts with early RA and poor prognostic factors were randomized to ABA+MTX or MTX alone for 12 months.<sup>1</sup> This was a <i>post hoc</i>, as-observed analysis of mean (95% CI) change from baseline (BL) to M12 in Genant-modified Sharp TS and HAQ-DI score according to DAS28, SDAI and CDAI status at M3, for pts with efficacy data available at BL, M6 and M12. <h3>Results</h3> Mean BL scores for disease activity, structural and functional status were similar between original treatment groups.<sup>1</sup> Change from BL to M12 in X-ray TS and HAQ-DI scores according to M3 disease activity status (low [LDA]; moderate [MDA]; high [HDA]) are shown. <h3>Conclusions</h3> This <i>post hoc</i> analysis indicated numerical trends that remission or LDA at M3 may be associated with less X-ray progression and greater functional improvements from BL to M12 than moderate/high disease at M3; somewhat less progression of X-ray score with ABA+MTX vs MTX alone was also observed in pts with moderate/high disease at M3, suggesting a protective effect of ABA on joint damage even in these pts; ABA+MTX conferred greater reductions in HAQ-DI score vs MTX alone, regardless of disease activity. <h3>References</h3> Westhovens R, et al. <i>Ann Rheum Dis</i> 2009;<b>68</b>:1870–7 <h3>Disclosure of Interest</h3> J. Smolen Grant/research support from: Abbott, Bristol-Myers Squibb, Hoffmann-La Roche, Schering-Plough, UCB, Pfizer, Consultant for: Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, Centocor, Eli-Lilly, Merck, Novo Nordisk, Roche, sanofi-aventis, UCB, Y. Yazici Grant/research support from: Centocor, Bristol-Myers Squibb, Genentech, Consultant for: Bristol-Myers Squibb, Celgene, Genentech, Horizon, UCB, Roche, Pfizer, Speakers bureau: Bristol-Myers Squibb, J. Wollenhaupt Consultant for: Bristol-Myers Squibb, Chugai, Roche, Speakers bureau: Chugai, Roche, P. Durez Speakers bureau: Bristol-Myers Squibb, J. Gomez-Reino Grant/research support from: Roche, Schering-Plough, Wyeth Pharmaceuticals, UCB, Consultant for: Hoffmann-La Roche, Roche, Schering-Plough, UCB, Pfizer, Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Roche, UCB, MSD, Pfizer, Abbott, W. Grassi Grant/research support from: Abbott, Bristol-Myers Squibb, Esaote, General Electric, Menarini, Merck Sharp &amp; Dohme, Pfizer, Roche, Schering-Plough, UCB, Consultant for: Abbott, Bristol-Myers Squibb, Esaote, General Electric, Menarini, Merck Sharp &amp; Dohme, Pfizer, Roche, Schering-Plough, UCB, M. Le Bars Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, C. Gaillez Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, C. Poncet Consultant for: Bristol-Myers Squibb, R. Westhovens Grant/research support from: Roche, UCB, Consultant for: Bristol-Myers Squibb, Galapagos, Janssen, Speakers bureau: Bristol-Myers Squibb